Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | DRD2 | P14416 | 8/20 | 0.37 |
| ▸ | DRD1 | P21728 | 3/20 | 0.37 |
| ▸ | DRD5 | P21918 | 3/20 | 0.37 |
| ▸ | DRD4 | P21917 | 3/20 | 0.37 |
| ▸ | DRD3 | P35462 | 2/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 6/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5525445 | 0.94 | DRD2 (0.38) | MEN1KMT2ADRD2DRD1DRD5 | |
| SCHEMBL2783246 | 0.88 | DRD2 (0.37) | MEN1KMT2ADRD2DRD1DRD5 | |
| SCHEMBL3772533 | 0.87 | SIGMAR1 (0.39) | MEN1KMT2ADRD2DRD1DRD5 | |
| SCHEMBL3767620 | 0.86 | DRD2 (0.39) | MEN1KMT2ADRD2DRD1DRD5 | |
| SCHEMBL2783420 | 0.86 | DRD2 (0.37) | MEN1KMT2ADRD2DRD1DRD5 | |
| SCHEMBL3761431 | 0.84 | DRD2 (0.44) | MEN1KMT2ADRD2DRD3P2RX7 | |
| SCHEMBL3764817 | 0.83 | MEN1 (0.38) | MEN1KMT2ADRD2DRD1DRD5 | |
| SCHEMBL2783391 | 0.83 | DRD2 (0.54) | MEN1KMT2ADRD2DRD1DRD5 | |
| SCHEMBL2785522 | 0.83 | DRD2 (0.39) | MEN1KMT2ADRD2DRD1DRD5 | |
| SCHEMBL3765947 | 0.82 | DRD2 (0.57) | DRD2DRD1DRD5DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851629-B2 | Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-12-14 | — | — | US | claimed |
| EP-1768958-B1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2009-11-18 | — | — | EP | claimed |
| US-20070179185-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2007-08-02 | — | — | US | claimed |
| US-7851629-B2 | Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-12-14 | — | — | US | disclosed |
| EP-1768958-B1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2009-11-18 | — | — | EP | disclosed |
| US-20070179185-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179185-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF DOPAMINE AND SEROTONIN NEUROTRANSMISSION | DRD2, DRD4, HTR4 | MEN1 3429/4885KMT2A 3190/4885DRD2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.